{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey amongst gastroenterologists to understand prevalence, patient profile and management of Erosive Esophagitis
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. What percent of GERD patients have EE in your practice? *

  2. What is the most common age group of patients you encounter with complaints of EE? *

  3. What are the most common symptoms observed in your patients with erosive esophagitis? (Select all that apply.) *

  4. Which of the following comorbidities have you commonly observed in patients with EE in your practice? (Select all that is applicable.)*

  5. What are the most common overlapping conditions observed in your EE patients? (Please tick all that is applicable) *

  6. How often do you use endoscopy to confirm the diagnosis of EE? *

  7. Which factors do you consider most when choosing treatment for erosive esophagitis? (Please tick all that is applicable) *

  8. What challenges do you face in the diagnosis of erosive esophagitis? *
  9. Which class of acid-suppressive therapy do you prefer as first-line treatment for Erosive Esophagitis? *

  10. How often do you prescribe PPIs as first-line therapy for erosive esophagitis? *

  11. In your practice, what is the proportion of EE patients with each of the LA grades? *

    12. A

    B

    C

    D

  12. How important is rapid symptom relief in your choice of treatment for management of EE? *

  13. What is the most common reason for treatment failure with PPIs in your patients? *

  14. Based on your experience, how do PCABs (Potassium Competitive Acid Blockers) perform in managing EE cases that are refractory to PPIs? *

  15. In most of your patients with EE, what is your preferred treatment duration with PCABs? *

  16. How would you compare PCABs to PPIs in terms of onset of action? *

  17. In your clinical experience, which treatment provides better nocturnal acid control ? *

  18. Do you foresee PCABs replacing PPIs as the first-line therapy for erosive esophagitis in the future? *

  19. How often do patients report improved symptom relief with PCABs compared to PPIs? *

  20. What are the goals of treatment for EE? *

  21. Which of the following lifestyle modifications do you commonly recommend to EE patients? (Select all that is applicable.) *

  22. Are you satisfied with the healing rates of erosive esophagitis with PCABs? *
  23. In terms of drug-drug interactions, do you consider PCABs better than PPIs? *

  24. How would you compare the mucosal healing rates of PCABs to PPIs in patients with severe erosive esophagitis (Los Angeles Grade B/C/D) *

  25. How do you determine the need for long-term acid suppression therapy in erosive esophagitis? *

  26. In patients with EE, what is your choice of long-term treatment pattern? *

  27. Which patient population do you consider most suitable for PCAB therapy over PPIs? (Please tick all that is applicable) *

  28. When treating severe erosive esophagitis (Los Angeles Grade C/D), what is your preferred approach? *
  29. For H. pylori eradication, do you prefer PCABs over PPIs for acid suppression? *
  30. In terms of acid suppression, do you believe PCABs provide superior 24-hour control compared to PPIs? *
  31. Are you satisfied with the long-term healing rates of erosive esophagitis with PCABs? *

  32. What is your experience on the impact of PCABs on gastric pH levels compared to PPIs? *

  33. Which EE patient populations do you think benefit most from PCABs over PPIs? (Select all that apply.) *

  34. What additional real-world evidence or clinical trials would increase your confidence in using PCABs for long-term maintenance therapy? *
  35. Which factors would influence your decision to prescribe PCABs more frequently in the future in EE patients? *
  36. What challenges do you face in diagnosing erosive esophagitis accurately? *
  37. Have you observed any differences in the recurrence rates of erosive esophagitis after discontinuing PCABs compared to PPIs? *
  38. In your experience, how do PCABs impact the overall patient treatment journey, including adherence and satisfaction? *
  39. How do you compare the improvement in Quality of Life provided by PCABs vs PPIs in EE patients? *
  40. How important is the lack of meal dependency for PCAB administration? *